You are receiving this as a medical professional who may be interested in clinical developments in widely discussed areas before they reach prime time
Investor Information Materials
Fortress Biotech Inc.
(Nasdaq: FBIO)
52-Week Range: $2.02 - $6.10
Recent Price: $4.11
Approx. MktCap: $399 Million
Fortress Biotech’s (FBIO) two most advanced programs are nearing key milestones expected in the second half of this year – initiation of a rolling New Drug Application (NDA) for Menkes Disease, a rare pediatric disorder, and release of topline data from a potentially pivotal trial of a Keytruda-like checkpoint inhibitor.

Article details near term milestones for candidates in cancer immunotherapy and Menkes Disease, a rare pediatric disorder.

In The News: Benzinga Interviews 
Fortress Biotech CEO Lindsay Rosenwald, MD

FBIO At A Glance

The helm of this $399 million market cap company is shared by two veteran biotech entrepreneurs, Lindsay Rosenwald, MD, and Michael Weiss (TG Therapeutics, Keryx, Cougar, etc.). Fortress secures medical assets from around the world, and clinically develops them to a point of monetization – whether it be out-licensing, co-development partnerships, or outright sale. Here we highlight two advanced programs in a portfolio of more than 25 preclinical to late-stage candidates, plus seven marketed products.

Fortress Biotech
Corporate Presentation

Slide Presentation

Visit Fortress Biotech's website

This material describes a medical industry investment opportunity and provides clinical awareness, depending on your specialty. Please see important disclaimer below.

Important notice, please read: The information and statistical data contained herein may contain forward-looking statements that reflect the company’s intentions, expectations, assumptions, or beliefs concerning future events, including, but not limited to, expectations with respect to FDA and other regulatory bodies approval of new products, technology, and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales, the size of market opportunities with respect to the company’s product candidates and sufficiency of the company’s cash flow for future liquidity and capital resource needs and other risks identified in the Risk Factor Section of the company’s Annual Report on Form 10-K and any subsequent reports filed with the SEC. We do not undertake to advise you as to any change in this information. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company’s research and development programs. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by subject company as an investor relations advisor, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.

Call 212 926-1733